ID: MRFR/HC/6887-HCR | 111 Pages | Published By Kinjoll Dey on March 2023
Diabetic Neuropathy Treatment Market is projected to grow at CAGR of 5.80% to reach USD 7,719.92 million by 2030.
Global Diabetic Neuropathy Treatment Market is expected to cross USD 7,719.92 million by 2030 at a CAGR of 5.80%.
The number of diabetic neuropathy cases is increasing globally, fueling market growth. Diabetic neuropathy treatment is the second-highest contributor to global disability and an estimated 30% to 40% of people across the globe live with diabetic neuropathy.
Diabetic neuropathy is most common in low- and middle-income countries, and this disorder requires lifelong care to manage.
The rising prevalence of diabetic disorders and increasing reimbursement offered to patients by health insurance providers.
Diabetic neuropathy treatment market was valued at USD 7,719.92 million in 2030.
The global market is expected to exhibit a strong 5.80% CAGR over the forecast period from 2020 to 2030.
The growing prevalence of diabetes is the major driver for the market.
The Americas are the leading regional market for diabetic neuropathy treatment due to the growing prevalence of diabetes in the region.
Leading players in the market include Abbott, Astellas Pharma, and Pfizer, among others.